Feb. 24 at 6:42 AM
🌅 4:00am EST Watchlist — February 24, 2026
$VIR – Major oncology deal: global collaboration with Astellas on VIR-5500 (PSMA dual-masked CD3 engager). Terms include
$335M upfront and near-term payments, up to
$1.37B milestones, and tiered double-digit royalties ex-US. Cost split 60% Astellas and 40% Vir, with 50 and 50 US profit and loss. Updated Phase 1 signals (PSA declines + responses at higher doses) add fuel to the expansion narrative. 🤝🧪
$SILO – Announced
$1.0M share repurchase authorization, but dilution optics matter: disclosed 848,320 shares issued to an investor relations consultant as a
$250K commitment fee. Watch how traders weigh buyback headline vs share supply. 💥🧾
$MYGN – Q4 revenue
$209.8M and FY revenue
$824.5M with adj EPS
$0.04. Reiterated FY26 guide: revenue
$860M–
$880M and adj EBITDA
$37M–
$49M, with focus on execution and cash position. 📊✅
Potential multi-day runners:
$GFAI ✅
$GNPX ✅
